Vaccine maker BioNTech has forecast a worse than expected slump in revenues this year as demand for coronavirus immunisation wanes, underlining the scale of the challenge facing companies that enjoyed windfalls from the pandemic.
疫苗制造商BioNTech预计，随着对冠状病毒免疫的需求减弱，该公司今年的营收将出现比预期更严重的下滑，这突显出从疫情中大赚一笔的公司所面临的挑战之大。
您已阅读7%（306字），剩余93%（3937字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。